249 related articles for article (PubMed ID: 34075766)
1. Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age.
Provenzano E
Acta Med Acad; 2021 Apr; 50(1):88-109. PubMed ID: 34075766
[TBL] [Abstract][Full Text] [Related]
2. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
[TBL] [Abstract][Full Text] [Related]
3. Pathological measurement and staging of residual breast cancer after neoadjuvant chemotherapy.
Harter D; O'Connor SM; Hertel JD; Calhoun BC
Histopathology; 2023 Sep; 83(3):453-464. PubMed ID: 37256703
[TBL] [Abstract][Full Text] [Related]
4. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer.
Leon-Ferre RA; Hieken TJ; Boughey JC
Ann Surg Oncol; 2021 Apr; 28(4):2111-2119. PubMed ID: 33486641
[TBL] [Abstract][Full Text] [Related]
5. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
6. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
7. The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making.
Whitehead I; Irwin GW; Bannon F; Coles CE; Copson E; Cutress RI; Dave RV; Gardiner MD; Grayson M; Holcombe C; Irshad S; O'Brien C; O'Connell RL; Palmieri C; Shaaban AM; Sharma N; Singh JK; Potter S; McIntosh SA;
BMC Cancer; 2021 Jan; 21(1):90. PubMed ID: 33482770
[TBL] [Abstract][Full Text] [Related]
8. When and how do I use neoadjuvant chemotherapy for breast cancer?
Rapoport BL; Demetriou GS; Moodley SD; Benn CA
Curr Treat Options Oncol; 2014 Mar; 15(1):86-98. PubMed ID: 24306808
[TBL] [Abstract][Full Text] [Related]
9. Pathologic evaluation of specimens after neoadjuvant chemotherapy in breast cancer: Current recommendations and challenges.
See SHC; Siziopikou KP
Pathol Res Pract; 2022 Feb; 230():153753. PubMed ID: 34990870
[TBL] [Abstract][Full Text] [Related]
10. Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial.
Thomas JSJ; Provenzano E; Hiller L; Dunn J; Blenkinsop C; Grybowicz L; Vallier AL; Gounaris I; Abraham J; Hughes-Davies L; McAdam K; Chan S; Ahmad R; Hickish T; Houston S; Rea D; Caldas C; Bartlett JM; Cameron DA; Hayward RL; Earl HM
Mod Pathol; 2017 Aug; 30(8):1069-1077. PubMed ID: 28548129
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer.
Wong SM; Almana N; Choi J; Hu J; Gagnon H; Natsuhara K; Shen AH; DeSantis S; Dominici L; Golshan M; Weiss A; Bellon J; Mittendorf EA; King TA
Ann Surg Oncol; 2019 Oct; 26(11):3502-3509. PubMed ID: 31228134
[TBL] [Abstract][Full Text] [Related]
12. The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery.
Youssef MMG; Metwally AA; Manie TM
J Egypt Natl Canc Inst; 2021 Feb; 33(1):5. PubMed ID: 33555499
[TBL] [Abstract][Full Text] [Related]
13. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant or adjuvant chemotherapy in early breast cancer?
Montemurro F; Nuzzolese I; Ponzone R
Expert Opin Pharmacother; 2020 Jun; 21(9):1071-1082. PubMed ID: 32237920
[TBL] [Abstract][Full Text] [Related]
15. Characterization and clinical impact of residual disease after neoadjuvant chemotherapy.
Viale G
Breast; 2013 Aug; 22 Suppl 2():S88-91. PubMed ID: 24074800
[TBL] [Abstract][Full Text] [Related]
16. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy.
Foldi J; Rozenblit M; Park TS; Knowlton CA; Golshan M; Moran M; Pusztai L
Curr Treat Options Oncol; 2021 Jul; 22(9):79. PubMed ID: 34213636
[TBL] [Abstract][Full Text] [Related]
17. Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients.
Bossuyt V; Spring L
Breast J; 2020 Jun; 26(6):1189-1198. PubMed ID: 32468652
[TBL] [Abstract][Full Text] [Related]
18. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy in the treatment of breast cancer.
Redden MH; Fuhrman GM
Surg Clin North Am; 2013 Apr; 93(2):493-9. PubMed ID: 23464698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
